A major advance in diabetes treatment is the finding that specific glucose-lowering drugs reduce the risk of cardiovascular disease. The results were tempered by the increased risk of amputations for the groups that received the SGLT2 inhibitor, canagliflozin. The generalizability of this finding is unknown. An understanding of the association of specific diabetes drugs with lower extremity complications will allow a better assessment of the risks and benefits for individual patients.
Idea No. 458